Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00227617 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00227617 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 36 participants.
The verdict
NCT00227617, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of neuroendocrine tumors by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of giving combination chemotherapy together with bevacizumab and to see how well it works in treating patients with advanced neuroendocrine tumors.
Interventions
- DRUG 5-fluorouracil
- DRUG oxaliplatin
- DRUG leucovorin
- BIOLOGICAL bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2005-06-08 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00227617
The ClinicalTrials.gov registry entry for NCT00227617 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 5-fluorouracil is the first listed.
NCT00227617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00227617 about?
NCT00227617 is a clinical study titled "Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors". RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Som...
What is the current status of trial NCT00227617?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2005-06-08. Estimated completion is 2016-02.
What interventions are being tested in trial NCT00227617?
The interventions under investigation include: 5-fluorouracil (DRUG), oxaliplatin (DRUG), leucovorin (DRUG), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00227617?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.